Welcome to the Lünemann Lab

The Lunemann lab focuses on understanding the immunology and pathogenesis of neuroinflammatory disease. We study a broad range of neurological disease conditions such as multiple sclerosis, neuromyelitis optica spectrum diseases including MOG-antibody associated disorders, autoimmune encephalitis, immune-mediated neuromuscular diseases including myasthenia gravis and inflammatory myopathies.

  • Antibody-mediated effector functions in neurological diseases

  • Role of B cells in T cell-mediated autoimmunity

  • Immune-modulatory functions of autophagy pathways in CNS diseases

Publications, past 2 years

Lünemann JD, von Gunten S, Neumann H. (2021) Targeting sialylation to treat central nervous system diseases. Trends Pharmacol. Sci., in press. IF 14.8

Lünemann JD. (2021) Getting specific: targeting Fc receptors in myasthenia gravis. Nat Rev Neurol. Aug 23. doi: 10.1038/s41582-021-00547-z. IF 42.9

Srimat Kandadai K, Kotur MB, Dokalis N, Amrein I, Keller CW, Münz C, Wolfer D, Prinz M, Lünemann JD. (2021) ATG5 in microglia does not contribute vitally to autoimmune neuroinflammation in mice. Autophagy. Feb 8:1-11. IF 16.0

Lünemann JD, Malhotra S, Shinohara ML, Montalban X, Comabella M. (2021) Targeting Inflammasomes to Treat Neurological Diseases. Ann Neurol. Aug;90(2):177-188. IF 10.4

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, …, Lünemann JD,… Tong CK (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. Jan;17(1):1-382. IF 16.0

Keller CW, Kotur MB, Mundt S, Dokalis N, Ligeon LA, Shah AM, Prinz M, Becher B, Münz C, Lünemann JD. (2021) CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation. Autophagy. May;17(5):1244-1258. IF 16.0

Keller CW, Münz C, Lünemann JD. (2020) Autophagy Pathways in CNS Myeloid Cell Immune Functions. Trends Neurosci. Dec;43(12):1024-1033. IF 13.8

Malhotra S, Costa C, Eixarch H, …, Lünemann JD, …, Comabella M. (2020) NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain. May 1;143(5):1414-1430. IF 13.5

Schorer M, Lambert K, Rakebrandt N, Rost F, Kao KC, Yermanos A, Spörri R, Oderbolz J, Raeber ME, Keller CW, Lünemann JD, Rogler G, Boyman O, Oxenius A, Joller N. (2020) Rapid expansion of Treg cells protects from collateral colitis following a viral trigger. Nat Commun. Mar 23;11(1):1522. IF 14.9

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. (2020) Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020 Jan;16(1):56-62. IF 42.9

For all publications, use ORCID ID link.